All In Biotech

Drug Trial Radar · NCT07361549

Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment

Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment: A Randomized, Double-Blinded, Parallel Phase 2 Clinical Trial

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Dec 2030

Study completion Jul 2031

Sponsor

Lead sponsor
Daniel A Tonetti, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
SNIS Foundation; Stryker Neurovascular
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test whether injecting lidocaine into two blood vessels of the brain can help treat chronic headaches (migraines)

Conditions

  • Refractory Migraine
  • Headache

Interventions

  • Lidocaine (drug)Drug

    Intra-arterial lidocaine infusion into bilateral middle meningeal arteries

  • SalineDrug

    Intra-arterial saline infusion into bilateral middle meningeal arteries

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Headache Impact Test-6 Scores (1 Month)Time frame: From baseline to 1 month follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cooper University Health Care

    Camden, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.